Methods of inhibiting metastases

• US 6,753,328 B2
• Filed: 10/01/2002
• Issued: 06/22/2004
• Est. Priority Date: 10/01/2001
• Status: Active Grant

• Current Assignee: Geistlich Pharma AG
• Original Assignee: Rhode Island Hospital
• Inventors: Wands, Jack R., Carlson, Rolf I., Maggio, Paul
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US10/262,778
• Publication Number:
  US 20030069229A1
• Time in Patent Office: 630 Days
• Field of Search: 514/222.5, 514/893, 604/890.1, 604/891.1, 604/892.1, 604/506, 604/507, 604/508, 604/510, 604/93.01, 604/264, 604/272, 604/6.16
• US Class Current: 514/222.5
• CPC Class Codes: A61K 31/549 having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.

Claims

1. A method of inhibiting the development of metastases of a primary tumor to a tissue of a liver, comprising:

(a) identifying an individual who is at risk of developing a metastatic liver tumor;

(b) isolating said liver from systemic circulation;

(c) directly contacting said tissue of said individual with taurolidine.

2. The method of claim 1, wherein said primary tumor is not a liver tumor.

3. The method of claim 1, wherein said primary tumor is in an organ of the peritoneal cavity.

4. The method of claim 1, wherein said individual is a mammal.

5. The method of claim 4, wherein said mammal is a human.

6. The method of claim 1, wherein said individual is identified as suffering from a colorectal tumor.

7. The method of claim 1, wherein said individual is identified as suffering from a tumor selected from the group consisting of a lung tumor, breast tumor, kidney tumor, colon tumor, esophageal tumor, testicular tumor, pancreatic tumor, melanoma, and choriocarcinoma.

8. The method of claim 1, wherein said Taurolidine is administered to said liver by perfusion in a direction of naturally-occurring blood flow.

9. The method of claim 1, wherein said liver is perfused with said taurolidine in situ.

10. The method of claim 1, wherein said Taurolidine is administered to said liver by retrograde perfusion.

11. The method of claim 8, wherein said perfusion is performed prior to excision of a primary tumor.

12. The method of claim 8, wherein said perfusion is carried out in conjunction with an abdominal surgery.

13. The method of claim 1, wherein said Taurolidine is administered by in-dwelling catheter.

14. The method of claim 1, wherein said Taurolidine is administered at a dose which increases caspase activity in a cell.

15. The method of claim 10, wherein said perfusion is performed prior to excision of a primary tumor.

16. The method of claim 10, wherein said perfusion is carried out in conjunction with an abdominal surgery.

20. The method of claim 1, wherein said taurolidine is administered to said organ by retrograde perfusion.

17. A method of inhibiting the development of metastases of a primary tumor to a tissue of an organ, comprising:

(a) identifying an individual who is at risk of developing a metastatic tumor;

(b) isolating said organ from systemic circulation;

(c) directly contacting said organ of said individual with taurolidine, wherein said organ comprises well defined input and output blood vessels.

18. The method of claim 17, wherein said organ is a kidney or a pancreas.

19. The method of claim 17, wherein said taurolidine is administered to said organ by perfusion in a direction of naturally-occurring blood flow.